DaVita Inc. (NYSE:DVA) Given Consensus Rating of “Hold” by Analysts

Shares of DaVita Inc. (NYSE:DVA) have been assigned a consensus rating of “Hold” from the five brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $157.00.

A number of equities analysts have commented on the stock. Truist Financial boosted their price target on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Tuesday, August 20th. UBS Group increased their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. TD Cowen increased their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Finally, Bank of America raised their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th.

DaVita Trading Up 1.0 %

Shares of NYSE:DVA opened at $165.19 on Thursday. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. The stock has a market capitalization of $13.86 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 0.90 and a beta of 0.87. DaVita has a 1-year low of $71.51 and a 1-year high of $166.02. The company has a 50 day moving average price of $145.73 and a 200 day moving average price of $140.27.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.47 by $0.12. The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. DaVita’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.08 EPS. On average, research analysts anticipate that DaVita will post 9.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the completion of the transaction, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at approximately $141,219,407.87. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Javier Rodriguez sold 32,176 shares of DaVita stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the transaction, the chief executive officer now owns 905,659 shares in the company, valued at $141,219,407.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. The disclosure for this sale can be found here. Insiders have sold a total of 113,601 shares of company stock worth $17,525,449 in the last quarter. 2.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On DaVita

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of DaVita by 60.2% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,498 shares of the company’s stock valued at $208,000 after buying an additional 563 shares during the period. Point72 Asset Management L.P. bought a new position in DaVita in the 2nd quarter valued at approximately $9,615,000. Chase Investment Counsel Corp acquired a new stake in shares of DaVita during the second quarter worth $2,933,000. B. Riley Wealth Advisors Inc. lifted its stake in shares of DaVita by 78.9% in the second quarter. B. Riley Wealth Advisors Inc. now owns 4,130 shares of the company’s stock valued at $572,000 after buying an additional 1,822 shares in the last quarter. Finally, Creative Planning increased its holdings in DaVita by 5.0% during the second quarter. Creative Planning now owns 8,297 shares of the company’s stock worth $1,150,000 after buying an additional 394 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.